Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01077154
Other study ID # 20060359
Secondary ID 2009-011299-32
Status Terminated
Phase Phase 3
First received
Last updated
Start date June 2, 2010
Est. completion date March 26, 2018

Study information

Verified date September 2021
Source Amgen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.


Description:

Eligible participants were randomized in a 1:1 ratio to receive denosumab 120 mg or placebo subcutaneously (SC) for up to 5 years. Randomization was stratified based on: 1. Breast cancer therapy/lymph node (LN) status: neoadjuvant therapy/any LN status versus adjuvant therapy/LN negative (based on axillary LN dissection, or based on sentinel node status) versus adjuvant therapy/LN positive 2. Hormone receptor (estrogen receptor [ER]/progesterone receptor [PR]) status: ER and/or PR positive versus ER and PR negative 3. Human epidermal growth factor receptor 2 (HER-2) status: HER-2 positive versus HER-2 negative 4. Age: < 50 years versus ≥ 50 years 5. Geographic Region: Japan versus Other regions. The primary analysis was conducted after all enrolled participants had the opportunity to complete 5 years of treatment from study day 1.


Recruitment information / eligibility

Status Terminated
Enrollment 4509
Est. completion date March 26, 2018
Est. primary completion date August 31, 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed, American Joint Committee on Cancer (AJCC) stage II or III breast cancer - High risk of breast cancer recurrence, defined as documented evidence of one or more of the following criteria: i) Biopsy evidence of breast cancer in regional lymph node(s) (LN) (node-positive disease); Nodal micrometastases only are not considered node positive ii) Tumor size > 5 cm (T3) or locally advanced disease (T4) - Documented pathological evaluation of the breast cancer for hormone receptor (estrogen receptor [ER] and progesterone receptor [PR]) status and HER-2 status - Subjects must be receiving or be scheduled to receive standard of care systemic adjuvant or neoadjuvant chemotherapy and/or endocrine therapy and/or HER-2 targeted therapy - For subjects receiving adjuvant therapy only: - subjects must have undergone complete resection of the primary tumor with clean surgical margins, or subjects must have undergone resection of the primary tumor and be scheduled for further treatment of the primary tumor with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomization - Time between definitive surgery and randomization must be = 12 weeks. Definitive surgery may include secondary interventions (e.g. to clear inadequate surgical margins) - Subjects with node positive disease must have undergone treatment of axillary LN with curative intent, or subjects must be scheduled for further treatment of regional lymph nodes with curative intent. Definitive treatment must be planned to be completed within approximately 9 months of randomization - Subjects must not have received prior neoadjuvant treatment. Endocrine treatment for less than 30 days prior to surgery is not considered prior neoadjuvant treatment - For subjects receiving neoadjuvant therapy only: - Time between start of neoadjuvant treatment and randomization must be = 8 weeks and subjects must be scheduled to undergo definitive treatment (including surgery and/or radiotherapy) with curative intent within approximately 9 months of starting neoadjuvant treatment - Female subjects with age = 18 years - Subjects with reproductive potential must have a negative pregnancy test within 14 days before randomization - Serum calcium or albumin-adjusted serum calcium = 2.0 mmol/L (8.0 mg/dL) and = 2.9 mmol/L (11.5 mg/dL) - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Written informed consent before any study-specific procedure is performed Exclusion Criteria: - Prior or current evidence of any metastatic involvement of any distant site - History of breast cancer (other than ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS]) prior to the current diagnosis - Osteoporosis requiring treatment at the time of randomization or treatment considered likely to become necessary within the subsequent six months - Any prior or synchronous malignancy (other than breast cancer), except i) Malignancy treated with curative intent and with no evidence of disease for = 5 years prior to enrollment and considered to be at low risk for recurrence by the treating physician ii) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease - Active infection with Hepatitis B virus or Hepatitis C virus - Known infection with human immunodeficiency virus (HIV) - Prior history or current evidence of osteomyelitis/osteonecrosis of the jaw - Active dental or jaw condition which requires oral surgery - Planned invasive dental procedure for the course of the study - Non-healed dental or oral surgery - Use of oral bisphosphonates within the past 1 year - Prior or current IV bisphosphonate administration - Prior administration of denosumab - Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or investigational drug study(s), or subject is receiving other investigational agent(s) - Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment. - Subject is of child bearing potential and is not willing to use, in combination with her partner, 2 highly effective methods of contraception or abstinence during treatment and for 5 months after the end of treatment - Subject has known sensitivity to any of the products to be administered during the study (e.g., mammalian derived products, calcium, or vitamin D) - Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures. - Any major medical or psychiatric disorder that in the opinion of the investigator prevent the subject from completing the study or interfere with the interpretation of the study results

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Administered subcutaneously for up to 5 years
Denosumab
Administered subcutaneously for up to 5 years

Locations

Country Name City State
Argentina Research Site Neuquen Neuquén
Argentina Research Site Provincia De Santa Fe Santa Fe
Argentina Research Site Quilmes Buenos Aires
Argentina Research Site Quilmes Buenos Aires
Argentina Research Site San Martin Buenos Aires
Argentina Research Site San Miguel de Tucuman Tucuman
Australia Research Site Bedford Park South Australia
Australia Research Site Bentleigh East Victoria
Australia Research Site Camperdown New South Wales
Australia Research Site Caringbah New South Wales
Australia Research Site East Melbourne Victoria
Australia Research Site Fitzroy Victoria
Australia Research Site Footscray Victoria
Australia Research Site Frankston Victoria
Australia Research Site Heidelberg Victoria
Australia Research Site Kogarah New South Wales
Australia Research Site Malvern Victoria
Australia Research Site Parkville Victoria
Australia Research Site Perth Western Australia
Australia Research Site Richmond Victoria
Australia Research Site Ringwood East Victoria
Australia Research Site Subiaco Western Australia
Australia Research Site Tweed Heads New South Wales
Australia Research Site Wahroonga New South Wales
Australia Research Site Warrnambool Victoria
Australia Research Site Wodonga Victoria
Belgium Research Site Antwerpen
Belgium Research Site Bonheiden
Belgium Research Site Brugge
Belgium Research Site Brussel
Belgium Research Site Bruxelles
Belgium Research Site Bruxelles
Belgium Research Site Edegem
Belgium Research Site Gent
Belgium Research Site Hasselt
Belgium Research Site Kortrijk
Belgium Research Site Leuven
Belgium Research Site Liège
Belgium Research Site Libramont
Belgium Research Site Namur
Belgium Research Site Oostende
Belgium Research Site Ottignies
Belgium Research Site Sint-Niklaas
Belgium Research Site Tournai
Belgium Research Site Wilrijk
Belgium Research Site Yvoir
Brazil Research Site Barretos São Paulo
Brazil Research Site Curitiba Paraná
Brazil Research Site ItajaÃ- Santa Catarina
Brazil Research Site Londrina Paraná
Brazil Research Site Porto Alegre Rio Grande Do Sul
Brazil Research Site Porto Alegre Rio Grande Do Sul
Brazil Research Site Porto Alegre Rio Grande Do Sul
Brazil Research Site São Paulo
Brazil Research Site São Paulo
Brazil Research Site Salvador Bahia
Brazil Research Site Salvador Bahia
Brazil Research Site Santo Andre São Paulo
Brazil Research Site Sao Paulo São Paulo
Bulgaria Research Site Plovdiv
Bulgaria Research Site Rousse
Bulgaria Research Site Sofia
Bulgaria Research Site Sofia
Bulgaria Research Site Stara Zagora
Bulgaria Research Site Varna
Bulgaria Research Site Veliko Tarnovo
Canada Research Site Barrie Ontario
Canada Research Site Brampton Ontario
Canada Research Site Calgary Alberta
Canada Research Site Edmonton Alberta
Canada Research Site Greenfield Park Quebec
Canada Research Site Kelowna British Columbia
Canada Research Site Kingston Ontario
Canada Research Site Kitchener Ontario
Canada Research Site Moncton New Brunswick
Canada Research Site Montreal Quebec
Canada Research Site Montreal Quebec
Canada Research Site Montreal Quebec
Canada Research Site Ottawa Ontario
Canada Research Site Quebec
Canada Research Site Sault Ste. Marie Ontario
Canada Research Site Sherbrooke Quebec
Canada Research Site St. John's Newfoundland and Labrador
Canada Research Site Sudbury Ontario
Canada Research Site Sydney Nova Scotia
Canada Research Site Toronto Ontario
Canada Research Site Toronto Ontario
Canada Research Site Victoria British Columbia
Chile Research Site Santiago
Chile Research Site Temuco CautÃ-n
Chile Research Site Vina del Mar ValparaÃ-so
Czechia Research Site Brno
Czechia Research Site Brno
Czechia Research Site Chomutov
Czechia Research Site Horovice
Czechia Research Site Hradec Kralove
Czechia Research Site Olomouc
Czechia Research Site Praha 10
Czechia Research Site Praha 10
Czechia Research Site Praha 4
Czechia Research Site Praha 5
Czechia Research Site Praha 8
Denmark Research Site Ã…rhus C
Denmark Research Site Herning
Denmark Research Site Vejle
Denmark Research Site Viborg
France Research Site Angers
France Research Site Bordeaux Cedex
France Research Site Dijon
France Research Site Grenoble
France Research Site Hyères
France Research Site Le Mans
France Research Site Lille
France Research Site Monaco
France Research Site Nantes Cedex 2
France Research Site Paris
France Research Site Pierre-Benite
France Research Site Saint Priest en Jarez Cedex
France Research Site Strasbourg cedex
France Research Site Villejuif cedex
Germany Research Site Berlin
Germany Research Site Berlin
Germany Research Site Bonn
Germany Research Site Bottrop
Germany Research Site Erlangen
Germany Research Site Frankfurt
Germany Research Site Kiel
Germany Research Site Koblenz
Germany Research Site München
Germany Research Site München
Germany Research Site München
Germany Research Site Mannheim
Germany Research Site Recklinghausen
Germany Research Site Rostock
Germany Research Site Tübingen
Germany Research Site Trier
Greece Research Site Athens
Greece Research Site Athens
Greece Research Site Heraklion
Greece Research Site Patra
Greece Research Site Thessaloniki
Greece Research Site Thessaloniki
Hong Kong Research Site Hong Kong
Hong Kong Research Site New Territories
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Debrecen
Hungary Research Site Gyor
Hungary Research Site Nyiregyhaza
Hungary Research Site Pecs
Hungary Research Site Szeged
Hungary Research Site Szekesfehervar
Hungary Research Site Szolnok
Hungary Research Site Zalaegerszeg
India Research Site Ahmednagar Maharashtra
India Research Site Aurangabad Maharashtra
India Research Site Bangalore Karnataka
India Research Site Chennai Tamil Nadu
India Research Site Hyderabad Andhra Pradesh
India Research Site Jaipur Rajasthan
India Research Site Madurai Tamil Nadu
India Research Site Miraj Maharashtra
India Research Site Mumbai Maharashtra
India Research Site Mumbai Maharashtra
India Research Site Nashik Maharashtra
India Research Site Nashik Maharashtra
India Research Site Pune Maharashtra
Ireland Research Site Cork
Ireland Research Site Dublin
Ireland Research Site Dublin
Ireland Research Site Dublin
Ireland Research Site Limerick
Ireland Research Site Waterford
Israel Research Site Ashkelon
Israel Research Site Haifa
Israel Research Site Jerusalem
Israel Research Site Kfar Sava
Israel Research Site Petah Tikva
Israel Research Site Poria Eylit
Israel Research Site Rehovot
Israel Research Site Tel Aviv
Israel Research Site Tel Aviv
Italy Research Site Ancona
Italy Research Site Bari
Italy Research Site Brescia
Italy Research Site Meldola FC
Italy Research Site Milano
Italy Research Site Monza (MB)
Italy Research Site Palermo
Italy Research Site Parma
Italy Research Site San Giovanni Rotondo FG
Italy Research Site Treviglio (BG)
Italy Research Site Varese
Japan Research Site Akashi-shi Hyogo
Japan Research Site Chuo-ku Tokyo
Japan Research Site Fukuoka-shi Fukuoka
Japan Research Site Hidaka-Shi Saitama
Japan Research Site Isehara-shi Kanagawa
Japan Research Site Kagoshima-shi Kagoshima
Japan Research Site Kitaadachi-gun Saitama
Japan Research Site Kitakyushu-shi Fukuoka
Japan Research Site Kumamoto-shi Kumamoto
Japan Research Site Kurashiki-shi Okayama
Japan Research Site Kure-shi Hiroshima
Japan Research Site Kurume-shi Fukuoka
Japan Research Site Kyoto-shi Kyoto
Japan Research Site Matsuyama-shi Ehime
Japan Research Site Miyazaki-shi Miyazaki
Japan Research Site Nagoya-shi Aichi
Japan Research Site Nagoya-shi Aichi
Japan Research Site Niigata-shi Niigata
Japan Research Site Osaka-shi Osaka
Japan Research Site Osaka-shi Osaka
Japan Research Site Shimotsuke-shi Tochigi
Japan Research Site Suita-shi Osaka
Japan Research Site Suntou-gun Shizuoka
Japan Research Site Tokyo
Japan Research Site Tokyo
Japan Research Site Tokyo
Japan Research Site Tokyo
Japan Research Site Utsunomiya-shi Tochigi
Korea, Republic of Research Site Goyang-si, Gyeonggi-do
Korea, Republic of Research Site Incheon
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Latvia Research Site Daugavpils
Latvia Research Site Liepaja
Latvia Research Site Riga
Malaysia Research Site Kota Bharu Kelantan
Malaysia Research Site Kuala Lumpur Wilayah Persekutuan
Malaysia Research Site Kuala Lumpur Wilayah Persekutuan
Malaysia Research Site Subang Jaya Selangor (incl. Putrajaya)
Mexico Research Site Colima
Mexico Research Site Distrito Federal
Mexico Research Site Durango
Mexico Research Site Leon Guanajuato
Mexico Research Site Mexico Distrito Federal
Mexico Research Site Mexico City Distrito Federal
Mexico Research Site Mexico City Distrito Federal
Mexico Research Site Monterrey Nuevo León
Mexico Research Site Pachuca de Soto Hidalgo
Mexico Research Site Queretaro Querétaro
Mexico Research Site San Luis Potosi San Luis PotosÃ-
Mexico Research Site Toluca
Netherlands Research Site Amsterdam
Netherlands Research Site Bergen op Zoom
Netherlands Research Site Breda
Netherlands Research Site Capelle aan den ijssel
Netherlands Research Site Den Haag
Netherlands Research Site Dordrecht
Netherlands Research Site Hoofddorp
Netherlands Research Site Leiden
Netherlands Research Site Nieuwegein
Netherlands Research Site Rotterdam
Netherlands Research Site Rotterdam
Netherlands Research Site Schiedam
Netherlands Research Site Sittard-Geleen
Netherlands Research Site Tiel
Netherlands Research Site Tilburg
Netherlands Research Site Venlo
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Philippines Research Site Cebu City
Philippines Research Site Manila
Philippines Research Site Manila
Philippines Research Site Metro Manila
Philippines Research Site Quezon City
Poland Research Site Gdansk
Poland Research Site Gdansk
Poland Research Site Krakow
Poland Research Site Olsztyn
Poland Research Site Poznan
Poland Research Site Rzeszow
Poland Research Site Szczecin
Portugal Research Site Lisboa
Portugal Research Site Lisboa
Portugal Research Site Porto
Portugal Research Site Porto
Portugal Research Site Santa Maria da Feira
Romania Research Site Bucharest
Romania Research Site Craiova
Romania Research Site Sibiu
Romania Research Site Suceava
Romania Research Site Timisoara
Russian Federation Research Site Barnaul
Russian Federation Research Site Chelyabinsk
Russian Federation Research Site Ivanovo
Russian Federation Research Site Kazan
Russian Federation Research Site Moscow
Russian Federation Research Site Saint Petersburg
Russian Federation Research Site Saint Petersburg
Serbia Research Site Belgrade
Serbia Research Site Nis
Slovakia Research Site Bardejov
Slovakia Research Site Kosice
Slovakia Research Site Michalovce
Slovakia Research Site Poprad
Slovakia Research Site Presov
Slovakia Research Site Spisska Nova Ves
Slovakia Research Site Trebisov
Slovenia Research Site Ljublijana
Slovenia Research Site Maribor
South Africa Research Site Cape Town
South Africa Research Site Groenkloof Gauteng
South Africa Research Site Johannesburg Gauteng
South Africa Research Site Pietermaritzburg
South Africa Research Site Port Elizabeth
South Africa Research Site Pretoria
South Africa Research Site Pretoria
Spain Research Site A Coruña Galicia
Spain Research Site A Coruña Galicia
Spain Research Site Alcorcón Madrid
Spain Research Site Badalona Cataluña
Spain Research Site Barcelona Cataluña
Spain Research Site Barcelona Cataluña
Spain Research Site Barcelona Cataluña
Spain Research Site Barcelona Cataluña
Spain Research Site Cádiz AndalucÃ-a
Spain Research Site Córdoba AndalucÃ-a
Spain Research Site Elche Comunidad Valenciana
Spain Research Site Girona Cataluña
Spain Research Site Jaén AndalucÃ-a
Spain Research Site Lleida Cataluña
Spain Research Site Málaga AndalucÃ-a
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Madrid
Spain Research Site Sabadell Cataluña
Spain Research Site Santander Cantabria
Spain Research Site Sevilla AndalucÃ-a
Spain Research Site Valencia Comunidad Valenciana
Spain Research Site Valencia Comunidad Valenciana
Spain Research Site Zaragoza Aragón
Taiwan Research Site Keelung City Keelung
Taiwan Research Site Putzu City Chiayi
Taiwan Research Site Tainan
Taiwan Research Site Taipei
Turkey Research Site Ä°zmir
Turkey Research Site Ankara
Turkey Research Site Ankara
Turkey Research Site Bornova-Izmir
United Kingdom Research Site Bebington
United Kingdom Research Site Birmingham
United Kingdom Research Site Brighton
United Kingdom Research Site Bristol
United Kingdom Research Site Cambridge
United Kingdom Research Site Dorset
United Kingdom Research Site Guildford
United Kingdom Research Site Leeds
United Kingdom Research Site London
United Kingdom Research Site London
United Kingdom Research Site Manchester
United Kingdom Research Site Manchester
United Kingdom Research Site Newcastle
United Kingdom Research Site Peterborough
United Kingdom Research Site Plymouth
United Kingdom Research Site Poole
United Kingdom Research Site Portsmouth
United Kingdom Research Site Sheffield
United Kingdom Research Site Truro
United States Research Site Abilene Texas
United States Research Site Alhambra California
United States Research Site Anaheim California
United States Research Site Ann Arbor Michigan
United States Research Site Annapolis Maryland
United States Research Site Asheville North Carolina
United States Research Site Athens Georgia
United States Research Site Baltimore Maryland
United States Research Site Bethesda Maryland
United States Research Site Beverly Hills California
United States Research Site Birmingham Alabama
United States Research Site Boston Massachusetts
United States Research Site Boynton Beach Florida
United States Research Site Campbell California
United States Research Site Cedar Rapids Iowa
United States Research Site Charleston South Carolina
United States Research Site Chattanooga Tennessee
United States Research Site Cincinnati Ohio
United States Research Site Columbia South Carolina
United States Research Site Columbia Maryland
United States Research Site Columbus Ohio
United States Research Site Coral Springs Florida
United States Research Site Corpus Christi Texas
United States Research Site Dallas Texas
United States Research Site Dallas Texas
United States Research Site Dallas Texas
United States Research Site Danvers Massachusetts
United States Research Site Denver Colorado
United States Research Site Denville New Jersey
United States Research Site Detroit Michigan
United States Research Site East Setauket New York
United States Research Site Edina Minnesota
United States Research Site El Paso Texas
United States Research Site Fort Lauderdale Florida
United States Research Site Fresno California
United States Research Site Fullerton California
United States Research Site Garland Texas
United States Research Site Germantown Tennessee
United States Research Site Grand Junction Colorado
United States Research Site Hackensack New Jersey
United States Research Site Henderson Nevada
United States Research Site Hershey Pennsylvania
United States Research Site High Point North Carolina
United States Research Site Hilton Head Island South Carolina
United States Research Site Hollywood Florida
United States Research Site Houston Texas
United States Research Site Houston Texas
United States Research Site Hutchinson Kansas
United States Research Site Indianapolis Indiana
United States Research Site Jackson Mississippi
United States Research Site Jacksonville Florida
United States Research Site Jefferson City Missouri
United States Research Site Jonesboro Arkansas
United States Research Site La Verne California
United States Research Site Lancaster California
United States Research Site Lebanon New Hampshire
United States Research Site Lincoln Nebraska
United States Research Site Long Beach California
United States Research Site Los Angeles California
United States Research Site Los Angeles California
United States Research Site Los Angeles California
United States Research Site Melbourne Florida
United States Research Site Minneapolis Minnesota
United States Research Site Nashville Tennessee
United States Research Site New Haven Connecticut
United States Research Site New York New York
United States Research Site New York New York
United States Research Site New York New York
United States Research Site Niles Illinois
United States Research Site Northridge California
United States Research Site Nyack New York
United States Research Site Paducah Kentucky
United States Research Site Pawtucket Rhode Island
United States Research Site Pittsburgh Pennsylvania
United States Research Site Plano Texas
United States Research Site Redondo Beach California
United States Research Site Richlands Virginia
United States Research Site Richmond Virginia
United States Research Site Roanoke Virginia
United States Research Site Saint Louis Park Minnesota
United States Research Site San Antonio Texas
United States Research Site San Antonio Texas
United States Research Site Santa Barbara California
United States Research Site Santa Maria California
United States Research Site Seattle Washington
United States Research Site Seattle Washington
United States Research Site Sioux Falls South Dakota
United States Research Site Tacoma Washington
United States Research Site Torrance California
United States Research Site Tucson Arizona
United States Research Site Tulsa Oklahoma
United States Research Site Tyler Texas
United States Research Site Wichita Kansas

Sponsors (2)

Lead Sponsor Collaborator
Amgen Daiichi Sankyo, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Belgium,  Brazil,  Bulgaria,  Canada,  Chile,  Czechia,  Denmark,  France,  Germany,  Greece,  Hong Kong,  Hungary,  India,  Ireland,  Israel,  Italy,  Japan,  Korea, Republic of,  Latvia,  Malaysia,  Mexico,  Netherlands,  Peru,  Philippines,  Poland,  Portugal,  Romania,  Russian Federation,  Serbia,  Slovakia,  Slovenia,  South Africa,  Spain,  Taiwan,  Turkey,  United Kingdom, 

References & Publications (2)

Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, Jandial D, Chan A. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020 Jan;21(1):60-72. doi: 10.1016/S1470-2045(19)30687-4. Epub 2019 Dec 2. — View Citation

Coleman R, Zhou Y, Jandial D, Cadieux B, Chan A. Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. Adv Ther. 2021 Aug;38(8):4569-4580. doi: 10.1007/s12325-021-01812-9. Epub 2021 Jun 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Bone Metastasis-free Survival (BMFS) BMFS time was defined as the time interval from the randomization date to the first occurrence of bone metastasis or death from any cause, whichever came first. Participants last known to be alive with no bone metastasis were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first occurrence of bone metastasis before randomization were censored at their randomization date.
Bone metastasis must have been confirmed by central imaging analysis or by biopsy, Evidence of disseminated tumor cells in bone marrow was not sufficient for determination of disease recurrence. Development of new primary malignancy in bone was not considered as bone metastasis.
Since the median BMSF time could not be estimated due to low number of events, the percentage of participants with an event (i.e., bone metastasis or death) is reported.
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
Secondary Disease-free Survival (DFS) DFS time was defined as the time interval from the randomization date to the date of first observation of disease recurrence or death from any cause, whichever was first. Participants last known to be alive with no disease recurrence were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first disease recurrence before randomization were censored at their randomization date.
Disease recurrence includes bone metastasis and extraosseous disease (EOD) confirmed by central imaging analysis or by biopsy/cytology. Development of non-breast cancer new primary malignancy was not considered as disease recurrence.
Since the median DFS time could not be estimated due to low number of events, the percentage of participants with an event (i.e., disease recurrence or death) is reported.
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
Secondary Disease-free Survival (DFS) in the Postmenopausal Subset DFS time was defined as the time interval from the randomization date to the date of first observation of disease recurrence or death from any cause, whichever was first. Participants last known to be alive with no disease recurrence were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first disease recurrence before randomization were censored at their randomization date.
Disease recurrence includes bone metastasis and extraosseous disease (EOD) confirmed by central imaging analysis or by biopsy/cytology. Development of non-breast cancer new primary malignancy was not considered as disease recurrence.
Since the median DFS time in the postmenopausal subset could not be estimated due to low number of events, the percentage of participants with an event (i.e., disease recurrence or death) is reported.
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
Secondary Overall Survival Overall survival (OS) time was defined as the time interval from the randomization date to the date of death from any cause. Participants last known to be alive were censored at their last contact date.
Since the median time to overall survival could not be estimated at the time of the final analysis due to low numbers of events, the percentage of participants with an event (i.e., death) is reported.
From randomization until the end of study; median (minimum, maximum) time on study was 72.7 (0, 92) and 72.3 (0, 92) months in each treatment group respectively.
Secondary Distant Recurrence-free Survival Distant recurrence-free survival (DRFS) was defined as the time interval from the randomization date to the date of first observation of distant disease recurrence or death from any cause, whichever came first. Participants last known to be alive, who had not experienced distant disease recurrence, were censored at their last assessment date, or at the primary analysis data cut-off date, whichever was first. Participants who had first distant recurrence before randomization were censored at their randomization date.
Distant disease recurrence includes confirmed bone metastasis and extraosseous disease other than local-regional disease recurrence. Development of non-breast cancer new primary malignancy was not considered as distant disease recurrence.
Since the median time to DRFS could not be estimated due to the low number of events, the percentage of participants with an event (i.e., distant recurrence or death) is reported.
From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A